Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023)
Pacific Biosciences Of California (PACB) posted quarterly Restructuring Costs of $63000.0 for Q4 2023, down 99.3% quarter-over-quarter from $9.0 million in Q3 2023.
Pacific Biosciences Of California (PACB) Restructuring Costs (2021 - 2023) Analysis & Trends
Pacific Biosciences Of California's Restructuring Costs history runs 2 years deep, the most recent figure standing at $63000.0 for Q4 2023.
- In Q4 2023, Restructuring Costs changed N/A year-over-year to $63000.0; the TTM figure through Dec 2024 stood at $9.0 million (changed N/A YoY), while the FY2023 annual figure was $9.0 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2023 stood at $63000.0, down from $9.0 million in the prior quarter.
- The five-year high for Restructuring Costs was $12.0 million in Q3 2021, with the low at $63000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.19 Bn | 194.59 Bn | 7.27 Bn |
| 2 | Stryker | 129.95 Bn | 126.47 Bn | 4.50 Bn |
| 3 | Medtronic | 120.06 Bn | 110.84 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.14 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.74 Bn | 48.49 Bn | 1.35 Bn |
| 6 | Dexcom | 34.60 Bn | 32.65 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.20 Bn | 32.10 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.13 Bn | 4.55 Bn |
| 9 | Steris | 23.25 Bn | 22.77 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 396.09 Mn | 159.21 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 63,000.00 |
| Sep 30, 2023 | 8.98 Mn |
| Dec 31, 2021 | 403,000.00 |
| Sep 20, 2021 | 12.00 Mn |